Rigel Pharmaceuticals (RIGL) Financial Statements & Analysis

Rigel Pharmaceuticals (RIGL) Income Statement

Rigel Pharmaceuticals reported revenue of $294.28M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 64.1% from $179.28M a year earlier. Net income was $367.02M, up 1999.1% year over year, a net margin of 124.7%. Gross margin was 93.3% and operating margin 42.6%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $78.70M, down 22.6% from the same quarter a year earlier.

Rigel Pharmaceuticals Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Rigel Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	294.28	179.28	116.88	115.74	149.24	108.62	59.29	44.51	4.48
Cost of Revenue	19.62	18.65	7.11	62.02	1.08	0.90	0.91	0.29	46.27
Gross Profit	274.66	160.63	109.77	118.49	148.15	107.73	58.38	44.22	-41.79
Operating Expenses
Research & Development	33.30	23.38	24.52	60.27	65.24	60.10	52.89	46.90	46.27
Selling, General & Administrative	115.90	113.06	105.74	112.45	91.89	76.60	74.59	70.00	37.83
Operating Expenses	149.20	136.44	130.26	174.04	157.13	136.70	127.47	116.91	84.10
Operating Income	125.47	24.19	-20.49	-55.55	-8.98	-28.97	-69.09	-72.68	-79.62
Other Income/Expense
Interest Income	3.68	2.09	2.27	0.68	0.05	0.58	2.53	2.20	0.89
Interest Expense	7.32	7.92	6.87	-3.71	4.86	1.35	0.34	0.00	0.00
Other Income/Expense	-3.64	-5.83	-4.60	-3.02	-3.52	-0.77	2.20	2.20	1.62
Income
Income Before Tax	121.83	18.37	-25.09	-58.57	-17.31	-29.74	-66.89	-70.48	-77.99
Income Tax Expense	-245.20	0.88	0.00	0.00	0.61	0.00	0.00	0.00	0.00
Net Income	367.02	17.49	-25.09	-58.57	-17.91	-29.74	-66.55	-70.48	-77.99
Net Income - Continuous Operations	367.02	17.49	-25.09	-58.57	-17.91	-29.74	-66.55	-70.48	-77.99
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	131.56	28.51	-16.98	-57.73	-11.29	-27.69	-65.88	-69.89	-77.53
EBIT	129.15	26.28	-18.22	-58.73	-12.45	-28.97	-	-	-
Depreciation & Amortization	2.42	2.23	1.24	1.00	1.16	0.71	0.68	0.59	0.47
Earnings Per Share
Basic EPS	20.00	1.00	-1.00	-3.00	-1.00	-2.00	-4.00	-4.00	-6.00
Diluted EPS	19.00	1.00	-1.00	-3.00	-1.00	-2.00	-4.00	-4.00	-6.00
Basic Shares Outstanding	17.99	17.58	17.40	17.05	17.05	16.88	16.72	16.05	12.63
Diluted Shares Outstanding	18.84	17.69	17.40	17.05	17.05	16.88	16.74	16.05	12.63

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Rigel Pharmaceuticals Financial Statements

What was Rigel Pharmaceuticals's revenue in fiscal 2025?

Rigel Pharmaceuticals reported revenue of $294.28M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 64.1% from $179.28M a year earlier.

Is Rigel Pharmaceuticals profitable?

Yes. Rigel Pharmaceuticals earned net income of $367.02M in fiscal 2025, a net margin of 124.7%. In fiscal 2024 it earned $17.48M.

What is Rigel Pharmaceuticals's operating margin?

Rigel Pharmaceuticals's operating income was $125.47M on revenue of $294.28M in fiscal 2025, an operating margin of 42.6%, compared with 13.5% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition